Hongtao Lu

Company: Elpiscience

Job title: CSO

Seminars:

Panel Discussion – Barriers to Development of CD73/CD39 Mono and Combo Therapies and Potential Solutions 11:00 am

Compare and contrast single vs dual inhibition of adenosine enzymes Explore current challenges with identifying and validating predictive biomarkers of response Suggest methods and technologies worth pursuing to better select patients for trialsRead more

day: Day Two

Targeting CD39-Adenosine Pathway for Immuno-Oncology 8:30 am

Why CD39 is an excellent target for cancer immune-oncology Preclinical characterization of eurestobart (ES002), Elpiscience’s anti-CD39 antibody Effect of ES014, a first-in-class bi-specific antibody targeting CD39 and TGF-beta, in modulating the immune system in the tumor microenvironment (TME)Read more

day: Day Two